查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370934

肺动脉高压市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类别、类型、给药途径、地区、竞争细分

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Type, By Route of Administration, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球肺动脉高压（PAH）市场估值达66.6亿美元，预计在整个预测期内将大幅成长，预计复合年增长率（CAGR）为5.32%，预计透过2020年将达到90.6亿美元。 2028. 肺动脉高血压是一种罕见但严重的疾病，其特征是肺动脉血压升高，肺动脉将血液从心臟输送到肺部。这种情况会导致这些动脉变窄和僵硬，增加心臟的压力，并可能导致心臟衰竭。

全球肺动脉高压 (PAH) 市场包括旨在管理和解决 PAH 的各种药品、医疗器材和治疗策略。医学理解、创新疗法和对 PAH 认识的最新发展是该市场成长的关键驱动力。促成这一增长的因素包括久坐生活方式和肥胖等危险因素导致多环芳烃患病率不断上升，以及患者和医疗保健专业人员诊断能力的提高和认识的提高。

药物介入在治疗 PAH 方面发挥关键作用，药物针对与疾病发病机制相关的特定途径。这些药物，如前列环素类似物、内皮素受体拮抗剂和 5 型磷酸二酯酶抑制剂，旨在扩张血管、降低动脉压并缓解疲劳和呼吸急促等症状。

市场概况
预测期 2024-2028
2022 年市场规模 66.6亿美元
2028 年市场规模 90.6亿美元
2023-2028 年复合年增长率 5.32%
成长最快的细分市场 磷酸二酯酶5
最大的市场 北美洲

此外，肺血管扩张帮浦等医疗设备和心室辅助装置等植入设备有助于治疗严重的肺动脉高压病例。除了传统疗法外，还建议改变生活方式和定期锻炼，以提高患者的生活品质。然而，多环芳烃市场仍存在挑战，包括治疗费用高昂和获得专业护理的机会有限。此外，PAH 诊断的复杂性和对专业知识的需求可能会阻碍及时介入。

主要市场驱动因素

  • 1. PAH 盛行率和认识不断提高：PAH 盛行率不断上升，对其严重性的认识不断提高，推动了 PAH 市场的扩张。公共卫生运动、改善的医学教育和患者倡导活动有助于早期诊断和介入。
  • 2.创新的治疗方法：针对PAH潜在机制的药物进步已经改变了治疗格局。创新药物和医疗设备正在改善患者的治疗结果和生活品质。
  • 3.个人化医疗：根据患者个别情况量身订做医疗服务是重要趋势。基因检测、分子分析和标靶治疗可优化治疗效果和患者参与度。

主要市场挑战

  • 1.高昂的治疗费用：PAH 药物、医疗设备和专业护理的费用给患者和医疗保健系统带来了财务挑战。获得有效治疗和综合护理的机会可能会受到影响。
  • 2.认识有限：患者和医疗保健专业人员缺乏认识会导致诊断延迟、护理欠佳和研究经费有限。透过教育和宣传提高认识至关重要。
  • 3.关键药物的专利到期：专利到期影响治疗的可近性、可负担性和创新性。在患者获得负担得起的治疗与药物创新之间取得平衡至关重要。

主要市场趋势

  • 1.合作研究和全球网络：国际伙伴关係和网络促进知识交流、跨学科方法以及加速创新疗法和治疗指南的发展。
  • 2.个人化治疗方法：由遗传学和分子谱驱动的个人化医疗正在改变 PAH 护理。精确的诊断和标靶治疗可提高治疗效果并增强患者的能力。

细分市场洞察

  • 1.药物类别洞察：磷酸二酯酶 5 抑制剂，如西地那非和他达拉非，由于能够鬆弛​​肺血管和缓解症状，在 PAH 市场中占据主导地位。
  • 2.类型见解：儘管有仿製药，但具有既定疗效和安全记录的品牌药物仍然是 PAH 治疗的主要选择。

区域洞察

由于先进的医疗基础设施、强大的研究计划和监管支持，北美在 PAH 市场中处于领先地位。医疗机构之间的合作、宣传活动和患者宣传工作有助于改善该地区的疾病管理和结果。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球肺动脉高压市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（前列环素和前列环素类似物、钙通道阻断剂、磷酸二酯酶 5、内皮素受体拮抗剂等）
    • 按类型（品牌、仿製药）
    • 依给药途径（口服、静脉/皮下、吸入）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美肺动脉高压市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按药物类别
    • 按类型
    • 依给药途径
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲肺动脉高压市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按药物类别
    • 按类型
    • 依给药途径
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区肺动脉高压市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按药物类别
    • 按类型
    • 依给药途径
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲肺动脉高压市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按药物类别
    • 按类型
    • 依给药途径
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲肺动脉高压市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按药物类别
    • 按类型
    • 依给药途径
    • 按国家/地区
  • MEA：国家分析
    • 南非 肺动脉高压
    • 沙乌地阿拉伯 肺动脉高压
    • 阿联酋肺动脉高压

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Gilead Sciences, Inc.
    • Viatris Inc.
    • Sandoz Inc. (Novartis)
    • Johnson & Johnson
    • Sun Pharmaceutical Industries, Inc.
    • Lupin Pharmaceuticals, Inc.
    • GlaxoSmithKline LLC
    • Johnson & Johnson
    • Bayer AG
    • United Therapeutics Corporation

第 16 章：策略建议

简介目录
Product Code: 15927

The Global Pulmonary Arterial Hypertension (PAH) Market reached a valuation of USD 6.66 Billion in 2022 and is expected to experience substantial growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.32% and expected to reach USD 9.06 Billion through 2028. Pulmonary Arterial Hypertension is a rare but serious medical condition characterized by elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This condition leads to the narrowing and stiffening of these arteries, placing increased strain on the heart and potentially resulting in heart failure.

The Global Pulmonary Arterial Hypertension (PAH) Market encompasses various pharmaceuticals, medical devices, and treatment strategies designed to manage and address PAH. Recent developments in medical understanding, innovative therapies, and heightened awareness of PAH have been key drivers of growth in this market. Factors contributing to this growth include the increasing prevalence of PAH due to risk factors like sedentary lifestyles and obesity, as well as improved diagnostic capabilities and heightened awareness among both patients and healthcare professionals.

Pharmaceutical interventions play a pivotal role in managing PAH, with drugs targeting specific pathways associated with the disease's pathogenesis. These medications, such as prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, aim to dilate blood vessels, reduce arterial pressure, and alleviate symptoms like fatigue and shortness of breath.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 6.66 Billion
Market Size 2028USD 9.06 Billion
CAGR 2023-20285.32%
Fastest Growing SegmentPhosphodiesterase 5
Largest MarketNorth America

Moreover, medical devices like pulmonary vasodilator pumps and implantable devices like ventricular assist devices contribute to managing severe cases of PAH. Alongside conventional therapies, lifestyle modifications and regular exercise are recommended to enhance patients' quality of life. However, challenges persist within the PAH market, including the high cost of treatment and limited access to specialized care. Additionally, the complexity of PAH diagnosis and the need for specialized expertise can hinder timely intervention.

The outlook of the market is characterized by ongoing research and development efforts focused on discovering novel therapies and improving treatment outcomes. Emerging trends such as personalized medicine approaches, biomarker identification, and combination therapies show promise in tailoring treatments to individual patient needs.

In conclusion, the Global Pulmonary Arterial Hypertension (PAH) Market is undergoing significant transformation due to innovative therapies and medical advancements. As awareness of the condition increases and research continues, the market is poised to witness further developments in diagnostics, treatment options, and patient care, ultimately leading to improved outcomes for those affected by this challenging medical condition.

Key Market Drivers

  • 1. Increasing Prevalence and Awareness of PAH: The rising prevalence of PAH and growing awareness of its severity have driven the expansion of the PAH Market. Public health campaigns, improved medical education, and patient advocacy initiatives have contributed to early diagnosis and intervention.
  • 2. Innovative Therapeutic Approaches: Pharmaceutical advancements targeting PAH's underlying mechanisms have transformed the treatment landscape. Innovative drugs and medical devices are improving patient outcomes and quality of life.
  • 3. Personalized Medicine: Tailoring medical care to individual patient profiles is a significant trend. Genetic testing, molecular profiling, and targeted therapies optimize treatment efficacy and patient engagement.

Key Market Challenges

  • 1. High Treatment Costs: The cost of PAH medications, medical devices, and specialized care poses financial challenges for patients and healthcare systems. Access to effective treatments and comprehensive care can be compromised.
  • 2. Limited Awareness: Lack of awareness among patients and healthcare professionals leads to delayed diagnosis, suboptimal care, and limited research funding. Raising awareness through education and advocacy is crucial.
  • 3. Patent Expiration of Key Drugs: Patent expiration affects treatment accessibility, affordability, and innovation. Balancing patients' access to affordable treatments with pharmaceutical innovation is essential.

Key Market Trends

  • 1. Collaborative Research and Global Networks: International partnerships and networks facilitate knowledge exchange, interdisciplinary approaches, and accelerated development of innovative therapies and treatment guidelines.
  • 2. Personalized Treatment Approaches: Personalized medicine, driven by genetics and molecular profiles, is transforming PAH care. Precise diagnostics and targeted therapies enhance treatment efficacy and patient empowerment.

Segmental Insights

  • 1. Drug Class Insights: Phosphodiesterase 5 inhibitors, such as sildenafil and tadalafil, dominate the PAH Market due to their ability to relax pulmonary blood vessels and alleviate symptoms.
  • 2. Type Insights: Branded medications, with established efficacy and safety records, continue to be the primary choice in PAH treatment, despite the availability of generics.

Regional Insights

North America leads the PAH Market due to advanced healthcare infrastructure, robust research initiatives, and regulatory support. Collaborations among medical institutions, awareness campaigns, and patient advocacy efforts contribute to improved disease management and outcomes in the region.

Key Market Players

  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Sandoz Inc. (Novartis)
  • Johnson & Johnson
  • Sun Pharmaceutical Industries, Inc.
  • Lupin Pharmaceuticals, Inc.
  • GlaxoSmithKline LLC
  • Johnson & Johnson
  • Bayer AG
  • United Therapeutics Corporation

Report Scope:

In this report, the Global Pulmonary Arterial Hypertension Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Pulmonary Arterial Hypertension Market, By Drug Class:

  • Prostacyclin and Prostacyclin Analogs
  • Calcium Channel Blockers
  • Phosphodiesterase 5
  • Endothelin Receptor Antagonist
  • Others

Pulmonary Arterial Hypertension Market, By Type:

  • Branded
  • Generics

Pulmonary Arterial Hypertension Market, By Route Of Administration:

  • Oral
  • Intravenous/ Subcutaneous
  • Inhalational

Global Pulmonary Arterial Hypertension Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Pulmonary Arterial Hypertension Market.

Available Customizations:

  • Global Pulmonary Arterial Hypertension Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Pulmonary Arterial Hypertension Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonist and Others)
    • 5.2.2. By Type (Branded, Generics)
    • 5.2.3. By Route Of Administration (Oral, Intravenous/ Subcutaneous, Inhalational)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Pulmonary Arterial Hypertension Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type
    • 6.2.3. By Route Of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pulmonary Arterial Hypertension Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Route Of Administration
    • 6.3.2. Mexico Pulmonary Arterial Hypertension Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Route Of Administration
    • 6.3.3. Canada Pulmonary Arterial Hypertension Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Route Of Administration

7. Europe Pulmonary Arterial Hypertension Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By Route Of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pulmonary Arterial Hypertension Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Route Of Administration
    • 7.3.2. Germany Pulmonary Arterial Hypertension Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Route Of Administration
    • 7.3.3. United Kingdom Pulmonary Arterial Hypertension Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Route Of Administration
    • 7.3.4. Italy Pulmonary Arterial Hypertension Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Route Of Administration
    • 7.3.5. Spain Pulmonary Arterial Hypertension Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Route Of Administration

8. Asia-Pacific Pulmonary Arterial Hypertension Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Route Of Administration
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pulmonary Arterial Hypertension Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Route Of Administration
    • 8.3.2. India Pulmonary Arterial Hypertension Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Route Of Administration
    • 8.3.3. South Korea Pulmonary Arterial Hypertension Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Route Of Administration
    • 8.3.4. Japan Pulmonary Arterial Hypertension Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Route Of Administration
    • 8.3.5. Australia Pulmonary Arterial Hypertension Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Route Of Administration

9. South America Pulmonary Arterial Hypertension Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By Route Of Administration
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pulmonary Arterial Hypertension Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Route Of Administration
    • 9.3.2. Argentina Pulmonary Arterial Hypertension Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Route Of Administration
    • 9.3.3. Colombia Pulmonary Arterial Hypertension Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Route Of Administration

10. Middle East and Africa Pulmonary Arterial Hypertension Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By Route Of Administration
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pulmonary Arterial Hypertension Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Route Of Administration
    • 10.3.2. Saudi Arabia Pulmonary Arterial Hypertension Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Route Of Administration
    • 10.3.3. UAE Pulmonary Arterial Hypertension Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Route Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Product & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Gilead Sciences, Inc.
    • 15.6.2. Viatris Inc.
    • 15.6.3. Sandoz Inc. (Novartis)
    • 15.6.4. Johnson & Johnson
    • 15.6.5. Sun Pharmaceutical Industries, Inc.
    • 15.6.6. Lupin Pharmaceuticals, Inc.
    • 15.6.7. GlaxoSmithKline LLC
    • 15.6.8. Johnson & Johnson
    • 15.6.9. Bayer AG
    • 15.6.10. United Therapeutics Corporation

16. Strategic Recommendations